31
Participants
Start Date
June 30, 2007
Primary Completion Date
July 31, 2009
Study Completion Date
February 28, 2013
Dasatinib (BMS-354825)
100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
Cetuximab (Erbitux, C225)
Loading dose of IV 400 mg/m\^2 on Day 1 of Cycle 1; IV 250 mg/m\^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
University of Pittsburgh Cancer Institute - Hillman Cancer Center, Pittsburgh
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
University of Pittsburgh
OTHER